Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canadian company, which develops barium, iodine and carbon active pharmaceutical ingredients. The Company is focused on producing its own barium, iodine and fullerene minerals. The Company, through its subsidiaries, Voyageur Industrial Minerals Ltd. and Voyageur Minerals Inc., is engaged in acquiring, exploring and developing raw materials for pharmaceutical products, primarily in the province of British Columbia, Canada and the state of Utah, United States. Its properties include Jubilee Mountain, Falcon and Paradox Basin. It owns a 100% interest in two barium sulphate (barite) projects, including the Frances Creek and Pedley Mountain property. It holds interests in a high-grade iodine, lithium, and bromine brine project situated in Utah, United States. It owns a 100% interest in two battery mineral projects that is focused on copper/zinc development. Its pipeline products include SmoothX 2.0%, MultiX Thick, MultiX Thin, HDX, LDX, VY-101 and VY-103.


TSXV:VM - Post by User

Post by whitenorth72on Dec 04, 2023 11:15am
247 Views
Post# 35767087

The next step.

The next step.I'm assuming the next step to unlocking government grants and funding is as follows.
From their last PR.

Due to the sole source environment in Canada for barium contrast agents, clients have asked Voyageur to produce a full suite of products to allow them to make a seamless transition to Voyageur's product line. In response to client demand, Voyageur is currently working with Alberta Veterinarian Laboratories (AVL) and its subsidiary Solvet https://solvet.ca/, to accelerate the formulation and testing of the remaining products that the market requires to ensure supply chain security for our clients. AVL is currently formulating the next 3 products with Health Canada licences; MultiXBa, MultiXs and MultiXthin. Upon completion of our full suite of products, Voyageur will begin penetrating the Canadian radiology market.
<< Previous
Bullboard Posts
Next >>